膜杰作
Star Staining
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
描述（Description）
The Human EGF R (Luc) HEK293 Reporter Cell was engineered to not only express STAT3 signaling response element, but also express the receptor full length human EGF R (Gene ID: 1956). When stimulated with human EGF protein, the EGF/EGF R interaction drives STAT3-mediated luminescence. Inhibition of EGF binding to EGF R by either anti-EGF or anti-EGF R antibodies results in a decrease in luminescence.
应用说明（Application）
1. Screen for anti-human EGF R or anti-human EGF neutralizing antibody.
2. Screen for human EGF R small molecule inhibitor
生长特性（Growth Properties）
Adherent
筛选标记（Selection Marker）
Hygromycin (40 μg/mL) + Puromycin (2 μg/mL)
培养基（Culture Medium）
DMEM medium + 10% FBS
冻存液（Freeze Medium）
Serum-free cell cryopreservation medium
装量（Quantity）
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
存储（Storage）
Frozen in liquid nitrogen.
支原体检测（Mycoplasma Testing）
Negative
无菌检测（Sterility Testing）
Negative
使用说明（Instructions for Use）
See data sheet for detailed culturing and assay protocol.
Receptor Assay
Expression analysis of human EGF R on Human EGF R (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human EGF R (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-EGF R antibody.
Protocol
Application
Inhibition of human EGF protein-induced reporter activity by anti-human EGF R neutralizing antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of human EGF protein (Cat. No. EGF-H52H3) with a final concentration of 50 ng/mL. The EC50 of anti-human EGF R neutralizing antibody (Cetuximab) is approximately 1.793 μg/mL.
Protocol
Inhibition of human EGF protein-induced reporter activity by human EGF R small molecule inhibitor.
This reporter cell was incubated with serial dilutions of inhibitors in the presence of human EGF protein (Cat. No. EGF-H52H3) with a final concentration of 50 ng/mL. The EC50 of human EGF R small molecule inhibitor (Erlotinib) was approximately 0.01 μM.
Protocol
Signaling Bioassay
Response to human EGF protein (RLU).
The Human EGF R (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human EGF protein (Cat. No. EGF-H52H3). The EC50 was approximately 56.23 ng/mL.
Protocol
Response to human EGF protein (Fold).
The Human EGF R (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human EGF protein (Cat. No. EGF-H52H3). The max induction fold was approximately 56.
Protocol
Passage Stability
Passage stability analysis by Signaling Bioassay.
The continuously growing Human EGF R (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human EGF protein. Human EGF protein stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 10-20.
Protocol
如有相关细胞池需求请联系我们
背景（Background）
The epidermal growth factor receptor (EGFR) belongs to the ErbB family of receptor tyrosine kinases (RTK). The aberrant activity of EGFR has shown to play a key role in the development and growth of tumor cells, where it is involved in numerous cellular responses including proliferation and apoptosis.
Limited Use&License Disclosure
- This cell line is provided for research use only. It is neither intended for any animal or human therapeutic use nor for any direct human in vivo use. You are restricted to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
- ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
- ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
- Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.
